The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Public ClinicalTrials.gov record NCT03487913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney Disease subjects with chronic kidney disease (CKD) in stages CKD1, CKD2 or CKD3.
Study identification
- NCT ID
- NCT03487913
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2018
- Primary completion
- Dec 1, 2019
- Completion
- Feb 10, 2020
- Last update posted
- Dec 4, 2022
2018 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palladio Biosciences Clinical Site | Los Angeles | California | 90022 | — |
| Palladio Biosciences Clinical Site | Jacksonville | Florida | 32216 | — |
| Palladio Biosciences Clinical Site | Miami | Florida | 33155 | — |
| Palladio Biosciences Clinical Site | Miami | Florida | 33165 | — |
| Palladio Biosciences Clinical Site | Palmetto Bay | Florida | 33157 | — |
| Palladio Biosciences Clinical Site | Tampa | Florida | 33612 | — |
| Palladio Biosciences Clinical Site | Baltimore | Maryland | 21201 | — |
| Palladio Biosciences Clinical Site | Rochester | Minnesota | 55902 | — |
| Palladio Biosciences Clinical Site | Kansas City | Missouri | 64111 | — |
| Palladio Biosciences Clinical Site | Laurelton | New York | 11413 | — |
| Palladio Biosciences Clinical Site | Indiana | Pennsylvania | 15701 | — |
| Palladio Biosciences Clinical Site | Nashville | Tennessee | 66160 | — |
| Palladio Biosciences Clinical Site | Salt Lake City | Utah | 84115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03487913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03487913 live on ClinicalTrials.gov.